Aduhelm | search
Click here to view Aduhelm news from 60+ newspapers.
Bookmark or Share- Biogen Abandons Its Controversial Alzheimer’s Drug AduhelmJan. 31, 2024. The drug maker Biogen said on Wednesday it would abandon its ownership rights to Aduhelm, an Alzheimer’s drug that had provoked fierce criticism of the company and regulators...
- FDA’s Decision to Approve New Treatment for Alzheimer’s DiseaseAduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of...
- ADUHELM® (aducanumab-avwa) | Official Patient SiteADUHELM attaches to and reduces amyloid plaques, a buildup of proteins in the brains of people with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease. Ask your doctor if ADUHELM is right for you. What are amyloid plaques? Amyloid plaques are clumps of protein that may: Build up in the brain over time.
- Aducanumab - WikipediaAducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer's disease (AD). It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai.
- Aduhelm: Side effects, cost, dosage, uses, and more - Medical News TodayAduhelm (aducanumab-avwa) is a prescription drug that treats Alzheimer’s disease. Learn about dosage, side effects, controversy over its approval, and more.
More
